Arbele Enters into Collaboration with BioAI on AI-Driven Precision Oncology
Thursday, October 10, 2024
Arbele has announced new strategic collaborations with BioAI in precision oncology, utilizing artificial intelligence (AI) to advance targeted immunotherapeutics, including bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs).
These partnerships focus on improving the quantification and prognostic prediction of cadherin-17 (CDH17) expression within tumor tissue and its immune microenvironment.
This is expected to expedite the development of companion diagnostics and effective clinical trials for advanced cancer treatment.
Arbele has formed a partnership with BioAI Health to develop a prototype algorithm for immunohistochemistry (IHC)-based quantification. The collaboration will leverage the PredictX platform, using clinical trial data from Arbele’s colorectal cancer biomarker screening studies.
The aim is to establish a gold standard companion diagnostic test for anti-CDH17 therapies, enabling improved patient selection and outcome predictions. This initiative highlights the use of AI in biomarker identification and patient stratification, focusing on CDH17 expression and its interaction with immune cells in the tumor environment.
Arbele has also partnered with Chime Biologics to accelerate the chemistry, manufacturing, and control (CMC) process development for novel ADCs and TCEs. This collaboration supports multiple immunotherapeutic pipelines, including monoclonal and bispecific antibodies.
Over the next three years, the partnership aims to advance approximately 10 first-in-class and best-in-class therapies, ensuring Arbele meets its goal of submitting at least one or two new molecular entities (NMEs) for investigational new drug (IND) applications within five years.
The first expected deliverable is the anti-CDH17 ADC (ARB102A), which is set for IND submission in early 2025.
Chime Biologics will provide continued support for Arbele's process development using the Quality-by-Design (QbD) strategy, enhancing global accessibility to innovative immunotherapeutic treatments.
Source: arbelebio.com
